Dan Cao
Division of Abdominal Tumor, Department of Medical Oncology, Cancer Center and State Key Laboratory of Biological Therapy, West China Hospital, Sichuan University, Chengdu, Sichuan · Jinhua Wenrong Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Dan Cao as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:53 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07802184 · GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic PDACWest China Hospital · recruiting · Metastatic Pancreatic Cancer · principal investigator
- Ph1NCT07409805 · YMN-136 Vaccine for Patients With Liver Metastasis of Colorectal Cancer Progressing After Third-Line TreatmentWest China Hospital · recruiting · Colorectal Cancer · principal investigator
- Ph1/Ph2NCT07175389 · JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment FailureWest China Hospital · not yet recruiting · Refractory Pancreatic Ductal Adenocarcinoma, Refractory Pancreatic Adenocarcinoma · principal investigator
- Ph2NCT07101679 · A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic CancerWest China Hospital · recruiting · Locally Advanced Pancreatic Ductal Adenocarcinoma · principal investigator
- N/ANCT07094022 · Improvement and Safety of Nutrilite Protein MetX Pro on Weight Management in Overweight Individuals With DyslipidemiaAmway (China) R&D Center · completed · Dyslipidemia, Obesity &Amp; Overweight · principal investigator
- N/ANCT06084585 · The Efficacy of Amway Uric Acid Lowering Product on HyperuricemiaAmway (China) R&D Center · unknown · Hyperuricemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Treatment-Related Cardiotoxicity Risk Prediction for Breast Cancer Patients with a Multimodal AI-based SystemR01CA301579 · NCI · OHIO STATE UNIVERSITY · fiscal years 2025 to 2026 · $641,078 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in pancreatic cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:53 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib/II trial.Signal Transduct Target Ther · 202432 citationsRCR 3.0
- 8 citationsRCR 2.1
- A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma.Oncologist · 20234 citationsRCR 0.4